loading page

Are Children with SARS-CoV-2 Infection at High Risk for Thrombosis? Viscoelastic Testing and Coagulation Profiles in a Case Series of Pediatric Patients
  • +9
  • Maha Al-Ghafry,
  • Banu Aygun,
  • Abena Appiah-Kubi,
  • Adrianna Vlachos,
  • Gholamabbas Ostovar,
  • Christine Capone,
  • Tod Sweberg,
  • Nancy Palumbo,
  • Pratichi Goenka,
  • Lawrence Wolfe,
  • Jeffrey Lipton,
  • Suchitra Acharya
Maha Al-Ghafry
Steven and Alexandra Cohen Children's Medical Center
Author Profile
Banu Aygun
Steven and Alexandra Cohen Children's Medical Center
Author Profile
Abena Appiah-Kubi
Steven and Alexandra Cohen Children's Medical Center
Author Profile
Adrianna Vlachos
Steven and Alexandra Cohen Children's Medical Center
Author Profile
Gholamabbas Ostovar
Steven and Alexandra Cohen Children's Medical Center
Author Profile
Christine Capone
Steven and Alexandra Cohen Children's Medical Center
Author Profile
Tod Sweberg
Steven and Alexandra Cohen Children's Medical Center
Author Profile
Nancy Palumbo
Steven and Alexandra Cohen Children's Medical Center
Author Profile
Pratichi Goenka
Steven and Alexandra Cohen Children's Medical Center
Author Profile
Lawrence Wolfe
Steven and Alexandra Cohen Children's Medical Center
Author Profile
Jeffrey Lipton
Steven and Alexandra Cohen Children's Medical Center
Author Profile
Suchitra Acharya
Steven and Alexandra Cohen Children's Medical Center
Author Profile

Abstract

The coagulopathy of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is well documented in adults, with increases in D-dimer and prothrombin time strong predictors of mortality and anticoagulation shown to decrease this mortality. Viscoelastic parameters such as elevations in maximum clot firmness (MCF) on rotational thromboelastometry (ROTEM) have correlated with a hypercoagulable state in adults with SARS-CoV-2. We report our experience in children infected with SARS-CoV-2, with noted elevations in D-dimer and MCF on ROTEM (indicating hypercoagulability). Exploration of viscoelastic testing to provide additional laboratory-based evidence for pediatric-specific risk-assessment for thromboprophylaxis in SARS-CoV-2 is warranted.

Peer review status:ACCEPTED

15 Jul 2020Submission Checks Completed
15 Jul 2020Assigned to Editor
15 Jul 2020Submitted to Pediatric Blood & Cancer
24 Jul 2020Reviewer(s) Assigned
28 Jul 2020Review(s) Completed, Editorial Evaluation Pending
06 Aug 2020Editorial Decision: Revise Minor
24 Aug 2020Submission Checks Completed
24 Aug 2020Assigned to Editor
24 Aug 20201st Revision Received
27 Aug 2020Reviewer(s) Assigned
10 Sep 2020Review(s) Completed, Editorial Evaluation Pending
13 Sep 2020Editorial Decision: Accept